Table 1. In- and exclusion criteria.

	Inclusion Criteria
1	Male or female patients aged 18 years or older
2	Caucasian
3	A clinical diagnosis of open-angle glaucoma, pseudoexfoliative or pigment dispersion glaucoma, or ocular hypertension in one or both eyes
4	Planned trabeculectomy with mitomycin C (MMC)
5	Previous treatment with antiglaucoma agents containing preservatives for at least one month
6	Best corrected visual acuity of 20/800 or better in the study eye
7	Ability of subject to understand the character and individual consequences of the clinical trial
8	Signed and dated informed consent of the subject was available before the start of any specific trial procedures
9	Women with childbearing potential had to practice medically accepted contraception during the trial, and a negative pregnancy test (serum or urine) had to exist before the trial.
	Exclusion Criteria
1	Secondary glaucoma except pseudoexfoliative glaucoma and pigmentary glaucoma
2	Current ocular infection; i.e., conjunctivitis or keratitis
3	Any abnormality preventing reliable applanation tonometry
4	Intraocular surgery or laser treatment within the past three months
5	History of surgery involving the conjunctiva
6	History of cataract surgery using the sclerocorneal approach
7	Allergy to sulphonamides
8	Reactive airway disease, including bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease
9	Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock
10	Severe renal dysfunction (CrCl < 30 ml/min) or hyperchloraemic acidosis
11	Depressed blood levels of sodium and/or potassium
12	Marked kidney and liver disease or dysfunction, gout, suprarenal gland failure, hypercalcinuria or nephrocalcinosis
13	History of hypersensitivity to the investigated medicinal products or to any drug with similar chemical structure or to any excipient present in the pharmaceutical formulation of the investigated medicinal products
14	Participation in other clinical trials during the present clinical trial or within the last four weeks
15	Medical or psychological conditions that would not permit completion of the trial or the signing of informed consent
16	Pregnancy and lactation